Ulka Vaishampayan, MD

Wayne State University

Detroit, Michigan

Dr. Ulka Vaishampayan is the Director of the Phase I program at the Barbara Ann Karmanos Cancer Institute, and the Chief of Solid Tumor Oncology in the Department of Oncology at Wayne State University in Detroit, Michigan. She is a Professor of Oncology at Wayne State University and is Associate Director of the Hematology/Oncology Fellowship Program. Dr. Vaishampayan has conducted clinical research in the management of GU cancers and clinical trials with a variety of novel agents in early therapeutics and translational settings. Her research interests also include working on evaluating novel pathways and biomarkers in cancers. She has contributed to many trials and clinical studies. She developed, conducted, and reported clinical studies in the field of early therapeutics, with a focus on GU malignancies. She is site PI of the UM-1 grant from the National Cancer Institute’s Early Therapeutics Cancer Research Network and is co-PI of the Prostate Cancer Clinical Trial consortium grant from the Department of Defense. She has recently obtained funding from the Gateway Foundation for a grant project and launched a trial entitled “Phase II trial of BATs and immune checkpoint inhibitor in metastatic prostate cancer.” In addition to these contributions, Dr. Vaishampayan has served as chair of the GU non-prostate track of the Education Committee of the American Society of Clinical Oncology. She was named chair of the Advanced Renal subcommittee within the GU committee of the Southwest Oncology Group in 2018. She has been published in a number of peer-reviewed journals, such as the Journal of Clinical Oncology, Clinical Cancer Research, Cancer, and Urology, and has been a co-author on a paper in the prestigious New England Journal of Medicine. She has also authored numerous review articles, editorials, and book chapters. She is an active reviewer for a number of journals, including the Journal of Clinical Oncology, Clinical Cancer Research, Journal of Urology, Urology, Cancer, and International Journal of Radiation Oncology, Biology and Physics. She is a board member of the Michigan Society of Hematology Oncology and organizes board review courses and ASCO update meetings.

Disclosures:

Articles by Ulka Vaishampayan, MD

Recent Clinical Radionuclide Therapy Advances in mCRPC

Posted by Ulka Vaishampayan, MD | Feb 2020

Ulka Vaishampayan, MD, Professor of Oncology at Wayne State University and Chief of Solid Tumor Oncology at the Karmanos Cancer Center, discusses the phase 3 randomized controlled trial of 177-Lutetium-PSMA radionuclide therapy. In this brief summary, Dr. Vaishampayan discusses the mechanism of action of this novel therapy, how to identify patients utilizing a PSMA-based PET scan, and the inclusion/exclusion criteria from the phase 3 randomized control trial of this targeted agent.

Ulka Vaishampayan, MD

Wayne State University

Detroit, Michigan

Articles by Ulka Vaishampayan, MD

Recent Clinical Radionuclide Therapy Advances in mCRPC

Join the GRU Community

You have Successfully Subscribed!

CARDEN JENNINGS PUBLISHING CO., LTD.

INFO

Your GRU

– Account Dashboard
– Your Courses

Recent Updates

Exercise & Wellness

Ulka Vaishampayan, MD

Wayne State University

Detroit, Michigan

Articles by Ulka Vaishampayan, MD

Recent Clinical Radionuclide Therapy Advances in mCRPC

Join the GRU Community

You have Successfully Subscribed!

CARDEN JENNINGS PUBLISHING CO., LTD.

INFO

Your GRU

– Account Dashboard – Your Courses

Recent Updates

Exercise & Wellness

– Account Dashboard
– Your Courses